Company intelligence / Profile preview

TheraMAB

Ownership: Private
Development stage: Other

Overview

TheraMAB developed theralizumab (TAB08/TGN1412), a humanized IgG4 monoclonal antibody targeting CD28 for autoimmune diseases and cancer. The drug was originally developed by TeGenero as TGN1412 but caused severe adverse events in its first-in-human trial in 2006. After TeGenero’s bankruptcy, rights were acquired by TheraMAB. Subsequent trials included Phase II for systemic lupus erythematosus and Phase I/II for plaque psoriasis; some trials were terminated due to administrative reasons or lack of progress. No recent clinical results are reported since 2021.

Therapeutic areas: DermatologyImmunologyOncology
Modalities: Monoclonal antibodyHumanized monoclonal antibody
Industry: Biotech

Partnerships

No major pharmaceutical partnerships reported post-acquisition from TeGenero

Beyond the preview

Go deeper on TheraMAB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraMAB.

Explore the full profile